Combination of low-dosage cyclosporine and topical pimecrolimus in severe atopic dermatitis with chronic hepatitis B [10]

Acta Dermato-Venereologica

Volumn 88, Issue 1, 2008, Pages 74-75

  Campione, Elena ^a   Paternò, Evelin Jasmine ^a   Diluvio, Laura ^a   Bianchi, Luca ^a   Giorgetti, Giammarco ^b   Chimenti, Sergio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; PIMECROLIMUS; STEROID;

ADULT; ANAMNESIS; ATOPIC DERMATITIS; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; HEPATITIS B; HUMAN; LETTER; LOW DRUG DOSE; PRIORITY JOURNAL; TREATMENT OUTCOME;

CALCINEURIN; CYCLOSPORINE; DERMATITIS, ATOPIC; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; SKIN; TACROLIMUS;

EID: 38949207215     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0327     Document Type: Letter

References (12)

1. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest 2004;113:651-657.
2. Bender BG, Leung SB, Leung DY. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure. J Allergy Clin Immunol 2003; 111: 598-602.
3. Meingassner JG, Kowalsky E, Schwendinger H, ElbeBurger A, Stutz A. Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol 2003; 149: 854-857.
4. Griffiths C, Katsambas A, Dijkmans B, Finlay AY, Ho VC, Johnston A, et al. Update on the use of Ciclosporin in immuno-mediated dermatoses. Br J Dermatol 2006; 155: 1-16.
5. Kakimi K, Guidotti L, Koezuka Y, Chiari FV1. Natural killer T-cell activation inhibits hepatitis B virus replication in vivo. J Exp Med 2000; 192: 921-930.
6. Xia WL, Shen Y, Zheng SS. Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms. Hepatobiliary Pancreat Dis Int 2005; 4: 18-22.
7. Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264-273.
8. Hultsch T, Müller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998; 290: 501-507.
9. Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Burger A. Pimecrolimus leads to an apoptosis induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005: 115: 1276-1283.
10. Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharmacol 2004; 269: 29-35.
11. Ishiwata N, Noguchi O, Koyama N, Sakamoto H, Hirata R, Enomoto N, et al. Treatment of acute severe exacerbation of chronic hepatitis B with cyclosporin A and interferon-β: a case report. Am J Gastroenterol 1995; 90: 5: 853-854.
12. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003; 38: 567-572.